Adicet Bio has dosed the first systemic sclerosis (SSc) subject in the Phase I trial’s second cohort evaluating ADI-001.

Vir Biotechnology has dosed the first subject in the non-randomised Phase I trial to assess VIR-5525, the investigational dual-masked TCE.

Windward Bio has launched the Phase II POLARIS trial of the recombinant, fully human monoclonal antibody, WIN378, in individuals with asthma.

ANI Pharmaceuticals has disclosed the outcomes of its NEW DAY trial, assessing Iluvien 0.19mg, in people with diabetic macular oedema.

Positive topline results of Apnimed's LunAIRo trial put AD109 on track for approval as the first oral sleep apnoea medication.

Monte Rosa Therapeutics has dosed the first participants in the Phase I trial of the NEK7-directed molecular glue degrader (MGD), MRT-8102.

The trail demonstrates that a swallowable, low-pill, non-absorbed iron polymer can match or exceed sevelamer in phosphate control.

AstraZeneca's Tagrisso combined with pemetrexed and platinum-based chemotherapy has shown improvement in overall survival (OS).

Industry experts have provided insight into how oncology clinical trials can be designed for success from the outset and rendered as patient-centric as possible.

Bristol Myers Squibb (BMS) has revealed that its Phase III trial assessing Reblozyl with JAKi therapy did not meet its primary goal.

Diakonos Oncology has dosed the first subject in its Phase II trial of DOC1021 for treating glioblastoma (GBM).

Sarepta Therapeutics’ share price has fallen again following the death of a third patient dosed with its gene therapy treatment.